Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
Guang Xu, … , Zhaofang Bai, Xiaohe Xiao
Guang Xu, … , Zhaofang Bai, Xiaohe Xiao
Published December 22, 2020
Citation Information: JCI Insight. 2021;6(2):e134601. https://doi.org/10.1172/jci.insight.134601.
View: Text | PDF
Research Article Immunology Inflammation

Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90

  • Text
  • PDF
Abstract

Aberrant activation of NLRP3 inflammasome has been implicated in a variety of human inflammatory diseases, but currently, no pharmacological NLRP3 inhibitor has been approved. In this study, we showed that echinatin, the ingredient of the traditional herbal medicine licorice, effectively suppresses the activation of NLRP3 inflammasome in vitro and in vivo. Further investigation revealed that echinatin exerts its inhibitory effect on NLRP3 inflammasome by binding to heat-shock protein 90 (HSP90), inhibiting its ATPase activity and disrupting the association between the cochaperone SGT1 and HSP90-NLRP3. Importantly, in vivo experiments demonstrated that administration of echinatin obviously inhibits NLRP3 inflammasome activation and ameliorates LPS-induced septic shock and dextran sodium sulfate–induced (DSS-induced) colitis in mice. Moreover, echinatin exerted favorable pharmacological effects on liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis (NASH). Collectively, our study identifies echinatin as a potentially novel inhibitor of NLRP3 inflammasome, and its use may be developed as a therapeutic approach for the treatment of NLRP3-driven diseases.

Authors

Guang Xu, Shubin Fu, Xiaoyan Zhan, Zhilei Wang, Ping Zhang, Wei Shi, Nan Qin, Yuanyuan Chen, Chunyu Wang, Ming Niu, Yuming Guo, Jiabo Wang, Zhaofang Bai, Xiaohe Xiao

×

Figure 1

Echinatin inhibits NLRP3 inflammasome activation in mouse BMDMs and human PBMCs.

Options: View larger image (or click on image) Download as PowerPoint
Echinatin inhibits NLRP3 inflammasome activation in mouse BMDMs and huma...
(A) The structure of echinatin (Echi) is shown. (B) Cell viability of BMDMs treated with an indicated dose of echinatin was assessed using Cell Counting Kit-8 (CCK-8) or CellTiter-Glo Assay, which is based on quantitation of ATP. (C–F) LPS-primed BMDMs were pretreated with various doses of echinatin and then stimulated with nigericin, cleaved caspase-1 and production of IL-1β (C). Activity of caspase-1 (D), secretion of IL-1β (E), and LDH (F) in SN were assessed. (G–J) LPS-primed human PBMCs were pretreated with various doses of echinatin and then stimulated with nigericin, cleaved caspase-1 and production of IL-1β (C). Activity of caspase-1 (D), secretion of IL-1β (E), and LDH (F) in SN were assessed. Data are expressed as mean ± SEM (n = 3/group, resulting from 3 independent experiments). One-way ANOVA, followed by Dunnett’s post hoc test, was used to assess the differences of multiple groups (B, D–F, and H–J). *P < 0.05, **P < 0.01, ***P < 0.001, ###P < 0.001 compared with control (B) or control with stimulated (D–F, H–J).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts